Linezolid interaction with serotonin reuptake inhibitors: Report of two cases and incidence assessment

Drug Metabolism and Drug Interactions

Volumn 25, Issue 1, 2010, Pages 41-47

  Go, Amy C ^a,b   Golightly, Larry K ^a,b   Barber, Gerard R ^a,b   Barron, Michelle A ^a,c  

^a UNIVERSITY OF COLORADO HOSPITAL   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressant; Interaction; Linezolid; Serotonin; Toxicity

Indexed keywords

CASPOFUNGIN; CILASTATIN PLUS IMIPENEM; CITALOPRAM; DOXYCYCLINE; DULOXETINE; ESCITALOPRAM; LINEZOLID; MYCOPHENOLIC ACID; RAPAMYCIN; SEROTONIN UPTAKE INHIBITOR; TACROLIMUS; VANCOMYCIN;

ADULT; AGED; ARTICLE; BACKACHE; BACTERIUM CULTURE; CANDIDIASIS; CLINICAL ARTICLE; CLONUS; COMPUTER ASSISTED TOMOGRAPHY; DECOMPRESSION SURGERY; DEPRESSION; DISEASE SEVERITY; DRUG INTERACTION; DRUG INTOXICATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENTEROBACTERIACEAE INFECTION; ENTEROCOCCAL INFECTION; FEMALE; HUMAN; HUNTER SEROTONIN TOXICITY CRITERIA; INCIDENCE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; MEDICAL RECORD; MENTAL DISEASE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; OSTEOMYELITIS; SEROTONIN TOXICITY; TACHYCARDIA; TOXICOLOGICAL PARAMETERS; TREMOR; VANCOMYCIN RESISTANT ENTEROCOCCUS INFECTION; VISUAL HALLUCINATION;

ACETAMIDES; ANTI-INFECTIVE AGENTS; CITALOPRAM; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; OXAZOLIDINONES; PAIN; SEROTONIN SYNDROME; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; STAPHYLOCOCCAL INFECTIONS; TREMOR;

EID: 79951488058     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: 10.1515/DMDI.2010.001     Document Type: Article

References (54)

1. Perry CM, Jarvis B. Linezolid: a review of its use in the management of serious gram-positive infections. Drugs 2001;61: 525 - 51. (Pubitemid 32368068)
2. Moellering RC Jr. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 2003;138:135 - 42. (Pubitemid 36222501)
3. Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 2003;42:1129 - 40. (Pubitemid 37357649)
4. Vardakas KZ, Kioumis I, Falagas ME. Association of pharmacokinetic and pharmacodynamic aspects of linezolid with infection outcome. Curr Drug Metab 2009;10:2 - 12.
5. Falagas ME, Vardakas KZ. Benefit-risk assessment of linezolid for serious gram-positive bacterial infections. Drug Saf 2008;31:753 - 68.
6. French G. Safety and tolerability of linezolid. J Antimicrob Chemother 2003;51(Suppl 2):45 - 53.
7. Plosker GL, Figgitt DP. Linezolid: a pharmacoeconomic review of its use in serious gram-positive infections. Pharmacoeconomics 2005;23:945 - 64. (Pubitemid 41317427)
8. Bounthavong M, Hsu DI, Okamoto MP. Cost-effectiveness analysis of linezolid vs. vancomycin in treating methicillinresistant Staphylococcus aureus complicated skin and soft tissue infections using a decision analytic model. Int J Clin Pract 2009;63:376 - 86.
9. Sola C, Bostwick JM, Hart DA, Lineberry TW. Anticipating linezolid- SSRI interactions in the general hospital setting: an MAOI in disguise. Mayo Clin Proc 2006;81:330 - 4. (Pubitemid 43334627)
10. Humphrey SJ, Curry JT, Turman CN, Stryd RP. Cardiovascular sympathomimetic amine interactions in rats treated with monoamine oxidase inhibitors and the novel oxazolidinone antibiotic linezolid. J Cardiovasc Pharmacol 2001;37:548 - 63. (Pubitemid 32377911)
11. Antal EJ, Hendershot PE, Batts DH, Shieu WP, Hopkins NK, Donaldson KM. Linezolid, a novel oxazolidinone antibiotic: assessment of monoamine oxidase inhibition using pressor response to oral tyramine. J Clin Pharmacol 2001;41:552 - 62. (Pubitemid 32381873)
12. Hendershot PE, Antal EJ, Welshman IR, Batts DH, Hopkins NK. Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorphan HBr. J Clin Pharmacol 2001;41:563 - 72. (Pubitemid 32381874)
13. Rubenstein E, Isturzi R, Standiford HC, Smith LG, Oliphant TH, Cammarata S, et al. Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob Agents Chemother 2003;47:1824 - 31. (Pubitemid 36637801)
14. Hyttel J. Neurochemical characterization of a new potent and selective serotonin uptake inhibitor: Lu 10-171. Psychopharmacology (Berl) 1977;51:225 - 33. (Pubitemid 8055394)
15. Pawlowski L, Ruczyńska J, Górka Z. Citalopram: a new potent inhibitor of serotonin (5-HT) uptake with central 5-HTmimetic properties. Psychopharmacology (Berl) 1981;74: 161 - 5. (Pubitemid 11126547)
16. Hyttel J, Bøgesø KP, Perregaard J, Sánchez C. The pharmacological effect of citalopram resides in the (S)-(+)enantiomer. J Neural Transm Gen Sect 1992;88:157 - 60.
17. Sánchez C, Bergqvist PB, Brennum LT, Gupta S, Hogg S, Larsen A, et al. Escitalopram, the S-(+) enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology (Berl) 2003;167:353 - 62. (Pubitemid 36754236)
18. Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. Q J Med 2003;96: 635 - 42. (Pubitemid 37063272)
19. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005;352:1112 - 20.
20. Horn JR, Hansten PD, Chan L-N. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 2007;41: 674 - 80. (Pubitemid 46625492)
21. Taylor JJ, Wilson JW, Estes LL. Linezolid and serotonergic drug interactions: a retrospective survey. Clin Infect Dis 2006; 43:180 - 7.
22. Lorenz RA, Vandenberg AM, Canepa EA. Serotonergic antidepressants and linezolid: a retrospective chart review and presentation of cases. Int J Psychiatry Med 2008;38:81 - 90.
23. Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with use of linezolid: a review of postmarketing data. Clin Infect Dis 2006;42:1578 - 83.
24. Gillman PK. A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. Biol Psychiatry 2006;59:1046 - 51. (Pubitemid 43849654)
25. Bernard L, Stern R, Lew D, Hoffmeyer P. Serotonin syndrome after concomitant treatment with linezolid and citalopram. Clin Infect Dis 2003;36:1197. (Pubitemid 36549644)
26. Zyvox [package insert]. New York, NY: Pharmacia & Upjohn, Division of Pfizer, 2008.
27. Thomas CR, Rosenberg M, Blythe V, Meyer WJ III. Serotonin syndrome and linezolid. J Am Acad Child Psychiatry 2004;43: 790.
28. Morales N, Vermette H. Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine. Psychosomatics 2004;46:274 - 5.
29. Steinberg M, Morin AK. Mild serotonin syndrome associated with concurrent linezolid and fluoxetine. Am J Health Syst Pharm 2007;64:59 - 62. (Pubitemid 46395709)
30. Hernández-Lorente E, Broto PL, Brumós LG, Simeón Aznar CP. Síndrome serotoninérgico desencadenado porlinezolid. Med Clin (Barc) 2009;132:157 - 8.
31. Clark DB, Andrus MR, Byrd DC. Drug interactions between linezolid and selective serotonin reuptake inhibitors: case report involving sertraline and review of the literature. Pharmacotherapy 2006;26:269 - 76. (Pubitemid 43201875)
32. Lavery S, Ravi H, McDaniel WW, Pushkin YR. Linezolid and serotonin syndrome. Psychosomatics 2001;42:432 - 4. (Pubitemid 33032117)
33. Hachem RY, Hicks K, Huen A, Raad I. Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients. Clin Infect Dis 2003;37:e8 - 11.
34. Morales-Molina JA, Mateu-de Antonio J, Grau Cerrato S, Marín Casino M. Probablesíndrome serotoninérgico por interacción entre amitriptilina, paroxetina y linezolid. Farm Hosp 2005;29:292 - 3.
35. Wigen CL, Goetz MB. Serotonin syndrome and linezolid. ClinInfect Dis 2002;34:1651 - 2. (Pubitemid 34615453)
36. Pearce S, Ahmed N, Varas GM. A case study of delayed serotonin syndrome: lessons learned. Consult Pharm 2009;24:64 - 8.
37. Jones SL, Athan E, O'Brien DO. Serotonin syndrome due to co-administration of linezolid and venlafaxine. J Antimicrob Chemother 2004;54:289 - 90. (Pubitemid 39029023)
38. Packer S, Berman SA. Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid. Am J Psychiatry 2007; 164:3476 - 7.
39. Mason LW, Randhawa KS, Carpenter EC. Serotonin toxicity as a consequence of linezolid use in revision hip arthroplasty. Orthopedics 2008;31:1140.
40. Bergeron L, Boulé M, Perreault S. Serotonin toxicity associated with concomitant use of linezolid. Ann Pharmacother 2005; 39:956 - 61. (Pubitemid 40570678)
41. Aga VM, Barklage NE, Jefferson JW. Linezolid, a monoamine oxidase inhibiting antibiotic, and antidepressants. J Clin Psychiatry 2003;64:609 - 11. (Pubitemid 36618294)
42. DeBellis RJ, Schaefer OP, Liquori M, Volturo GA. Linezolidassociated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient. J Intensive Care Med 2005;20:351 - 3.
43. Strouse TB, Kerrihard TN, Forscher CA, Zakowski P. Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine. J Clin Psychopharmacol 2006;26:681 - 3. (Pubitemid 44772758)
44. Tahir N. Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram. J Am Med Dir Assoc 2004;5:111 - 3. (Pubitemid 38380411)
45. Lee C. Therapeutic challenges in the era of antibiotic resistance. Int J Antimicrob Agents 2008;32(Suppl 4):197 - 9.
46. Rodríguez de Castro F, Naranjo OR, Marco JA, Violán JS. New antimicrobial molecules and new antibiotic strategies. Semin Respir Crit Care Med 2009;30:161 - 71.
47. Moreillon P. New and emerging treatment of Staphylococcus aureus infections in the hospital setting. Clin Microbiol Infect 2008;14(Suppl 3):32 - 41.
48. Johnson MD, Decker CF. Antimicrobial agents in treatment of MRSA infections. Dis Mon 2008;54:793 - 800.
49. Bishop E, Melvani S, Howden B, Charles PG, Grayson ML. Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. Antimicrob Agents Chemother 2006;50:1599 - 602.
50. Morales-Molina JA, Mateu-de Antonio J, Marín-Casino M, Grau S. Linezolid-associated serotonin syndrome: what we can learn from cases reported so far. J Antimicrob Chemother 2005;56:1176 - 8. (Pubitemid 43009846)
51. Baldwin DS, Montgomery SA, Nil R, Lader M. Discontinuation symptoms in depression and anxiety disorders. Int J Neuropsychopharmacol 2007;10:73 - 84. (Pubitemid 46122754)
52. Lejoyeux M, Adès J. Antidepressant discontinuation: a review of the literature. J Clin Psychiatry 1997;58(Suppl 7):11 - 6. (Pubitemid 27305034)
53. Schatzberg AF, Haddad P, Kaplan EM, Lejoyeux M, Rosen baum JF, Young AH, et al. Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical defi nition. J Clin Psychiatry 1997;58(Suppl 7):5 - 10. (Pubitemid 27305033)
54. Rosebaum JF, Zajecka J. Clinical management of antidepressant discontinuation. J Clin Psychiatry 1997;58(Suppl 7): 37 - 40. (Pubitemid 27305039)